10-amino-1mq
A small-molecule NNMT inhibitor under study for adipose-tissue NAD+ preservation and fat-mass reduction.
How it works
Inhibits nicotinamide N-methyltransferase (NNMT), conserving the NAD+ precursor nicotinamide. Elevated NAD+ in adipose tissue promotes lipolysis and oxidative metabolism.
Reported benefits
- Reduced fat mass without altering food intake in mouse studies
- Improved muscle stem-cell function in aged mice
Dosage & administration
Research range: 50-150 mg/day in animal studies, no human protocol established.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Pharmacological inhibition of NNMT in obesity
Biochemical Pharmacology · 2018
10-amino-1mq reduced adipose mass in DIO mice over 11 days.
Safety & warnings
- Long-term human data lacking
- Strict research use
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
10 mg
10AM
Box of 10 · $474
Single vial · $948
Related guides
Tirzepatide
A first-in-class dual GIP and GLP-1 receptor agonist that has reset the standard for pharmacologic weight loss.
Semaglutide
The long-acting GLP-1 analogue that opened the modern era of injectable weight management.
Retatrutide
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing unprecedented weight loss in phase-2 data.